Match!
Julie Gottlieb Fisher
Carolinas Healthcare System
PathologyOncologyPhases of clinical researchBreast cancerMedicine
8Publications
3H-index
13Citations
What is this?
Publications 8
Newest
Last. Richard L. SchilskyH-Index: 66
view all 15 authors...
Source
#1Ajjai Alva (UM: University of Michigan)H-Index: 19
#2Pam K. Mangat (American Society of Clinical Oncology)H-Index: 2
Last. Richard L. Schilsky (American Society of Clinical Oncology)H-Index: 66
view all 20 authors...
1014Background: TAPUR is a phase II basket study evaluating the anti-tumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. P is an...
Source
#1Amanda E.D. Van Swearingen (UNC: University of North Carolina at Chapel Hill)H-Index: 7
#2Marni B. Siegel (UNC: University of North Carolina at Chapel Hill)H-Index: 9
Last. Carey K. Anders (UNC: University of North Carolina at Chapel Hill)H-Index: 21
view all 24 authors...
Purpose HER2 + breast cancer (BC) is an aggressive subtype with high rates of brain metastases (BCBM). Two-thirds of HER2 + BCBM demonstrate activation of the PI3K/mTOR pathway driving resistance to anti-HER2 therapy. This phase II study evaluated everolimus (E), a brain-permeable mTOR inhibitor, trastuzumab (T), and vinorelbine (V) in patients with HER2 + BCBM.
5 CitationsSource
#1Antoinette R. Tan (Carolinas Healthcare System)H-Index: 27
#2Rebecca Feldman (Carolinas Healthcare System)H-Index: 3
Last. Edward KimH-Index: 29
view all 7 authors...
11581Background: Young women with breast cancer (YWBC; ≤40 years) have a more aggressive clinical course and is associated with a poorer prognosis. In this analysis, we explore molecular features i...
Source
#1Carey K. Anders (UNC: University of North Carolina at Chapel Hill)H-Index: 21
#2Allison M. DealH-Index: 31
Last. Lisa A. Carey (UNC: University of North Carolina at Chapel Hill)H-Index: 60
view all 20 authors...
1011Background: HER2+ BC is an aggressive subset of BC with high rates of BM and poor survival. Two-thirds of BCBM demonstrate activation of the PI3K/mTOR pathway driving resistance to anti-HER2 therapy (Rx). This phase II study evaluated everolimus (E), a brain permeable mTOR inhibitor, added to trastuzumab (T) and vinorelbine (V) in patients (pts) with HER2+ BCBM. Methods: Eligible pts had progressing HER2+ BCBM. Pts received E (5mg PO QD), T (2mg/kg IV weekly) and V (25mg/m2 IV d1, 8 of 21d c...
3 CitationsSource
#1C SauraH-Index: 8
#2Steven J. IsakoffH-Index: 36
view all 16 authors...
Background: TNBC often exhibits activation of PI3K/Akt signaling, associated with loss of PTEN expression, low INPP4B expression, and/or increased AKT3 amplification. Inhibition of the PI3K/Akt pathway in diverse cancers leads to radiosensitization and/or chemosensitization. Ipat is an oral, potent ATP-competitive small molecule inhibitor of all three isoforms of Akt. The combination of ipat with taxanes in preclinical models resulted in enhanced efficacy relative to either ipat or chemotherapy ...
2 CitationsSource
#1Steven J. Isakoff (Harvard University)H-Index: 36
#2Cristina SauraH-Index: 20
view all 18 authors...
TPS1105Background: TNBC often exhibits activation of PI3K/Akt signaling, associated with loss of PTEN expression, low INPP4B expression, PI3K/Akt mutations, or PI3K/AKT3 amplification. Inhibition of the PI3K/Akt pathway may lead to radiosensitization and/or chemosensitization. Ipatasertib (ipat) is an oral, potent ATP-competitive small molecule inhibitor of all three isoforms of Akt. The combination of ipat with taxanes in preclinical models resulted in enhanced efficacy relative to either ipat ...
3 CitationsSource
44 Background: Screening patients at high-risk for the development of breast cancer consists of MRI and mammography. This retrospective review of screening MRIs in patients designated as high-risk for the development of breast cancer--based on family history alone or a calculated lifetime risk of ≥ 20%--seeks to determine the utility of MRI screening in the detection of early-stage breast cancer. The primary outcome evaluated was stage of malignancy detected through screening imaging. Methods: R...
Source
1